CL2023001221A1 - Agonista del receptor de melanocortina-4 amorfo - Google Patents
Agonista del receptor de melanocortina-4 amorfoInfo
- Publication number
- CL2023001221A1 CL2023001221A1 CL2023001221A CL2023001221A CL2023001221A1 CL 2023001221 A1 CL2023001221 A1 CL 2023001221A1 CL 2023001221 A CL2023001221 A CL 2023001221A CL 2023001221 A CL2023001221 A CL 2023001221A CL 2023001221 A1 CL2023001221 A1 CL 2023001221A1
- Authority
- CL
- Chile
- Prior art keywords
- amorphous
- melanocortin
- receptor agonist
- formula
- compound represented
- Prior art date
Links
- 102000001796 Melanocortin 4 receptors Human genes 0.000 title 1
- 108010021436 Type 4 Melanocortin Receptor Proteins 0.000 title 1
- 239000000018 receptor agonist Substances 0.000 title 1
- 229940044601 receptor agonist Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 238000002441 X-ray diffraction Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000001757 thermogravimetry curve Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrane Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente invención se relaciona a un compuesto amorfo representado por la fórmula 1, un método para preparar el mismo, y una composición farmacéutica que comprende el mismo. El compuesto amorfo representado por la fórmula 1 de la presente invención se puede caracterizar por patrones XRD, perfiles DSC y/o perfiles TGA.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20200142399 | 2020-10-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2023001221A1 true CL2023001221A1 (es) | 2023-11-03 |
Family
ID=81384115
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2023001221A CL2023001221A1 (es) | 2020-10-29 | 2023-04-27 | Agonista del receptor de melanocortina-4 amorfo |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP4219471A4 (es) |
| JP (1) | JP2023548162A (es) |
| KR (1) | KR20220057469A (es) |
| CN (1) | CN116419757A (es) |
| AU (1) | AU2021370071B2 (es) |
| CA (1) | CA3195214A1 (es) |
| CL (1) | CL2023001221A1 (es) |
| CO (1) | CO2023006514A2 (es) |
| IL (1) | IL302425A (es) |
| MX (1) | MX2023004654A (es) |
| PE (1) | PE20231379A1 (es) |
| WO (1) | WO2022092908A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2024500906A (ja) * | 2020-12-22 | 2024-01-10 | エルジー・ケム・リミテッド | 無定形のメラノコルチン受容体アゴニストおよびその製造方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000074679A1 (en) * | 1999-06-04 | 2000-12-14 | Merck & Co., Inc. | Substituted piperidines as melanocortin-4 receptor agonists |
| US7157463B2 (en) * | 2001-01-23 | 2007-01-02 | Eli Lilly And Company | Substituted piperidines/piperazines as melanocortin receptor agonists |
| AR044510A1 (es) | 2003-04-14 | 2005-09-14 | Merck & Co Inc | Procedimiento e intermedios para preparar acidos carboxilicos de pirrolidina |
| WO2005047251A1 (en) * | 2003-11-12 | 2005-05-26 | Lg Life Sciences Ltd. | Melanocortin receptor agonists |
| TWI332501B (en) | 2006-07-14 | 2010-11-01 | Lg Life Sciences Ltd | Melanocortin receptor agonists |
| UA99555C2 (en) * | 2008-11-12 | 2012-08-27 | Элджи Лайф Саенсез Лтд. | Melanocortin receptor agonists |
| CA3053168A1 (en) | 2017-02-08 | 2018-08-16 | Tilray, Inc. | Methods and apparatus for low-pressure radiant energy processing of cannabis |
| PT3953327T (pt) * | 2019-11-07 | 2024-02-05 | Lg Chemical Ltd | Agonistas do recetor de melanocortina-4 |
-
2021
- 2021-10-29 JP JP2023526433A patent/JP2023548162A/ja active Pending
- 2021-10-29 AU AU2021370071A patent/AU2021370071B2/en active Active
- 2021-10-29 WO PCT/KR2021/015467 patent/WO2022092908A1/ko active Application Filing
- 2021-10-29 IL IL302425A patent/IL302425A/en unknown
- 2021-10-29 KR KR1020210146187A patent/KR20220057469A/ko not_active Application Discontinuation
- 2021-10-29 CA CA3195214A patent/CA3195214A1/en active Pending
- 2021-10-29 PE PE2023001493A patent/PE20231379A1/es unknown
- 2021-10-29 EP EP21886902.2A patent/EP4219471A4/en active Pending
- 2021-10-29 CN CN202180072880.1A patent/CN116419757A/zh active Pending
- 2021-10-29 MX MX2023004654A patent/MX2023004654A/es unknown
-
2023
- 2023-04-27 CL CL2023001221A patent/CL2023001221A1/es unknown
- 2023-05-17 CO CONC2023/0006514A patent/CO2023006514A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2021370071A1 (en) | 2023-06-01 |
| EP4219471A1 (en) | 2023-08-02 |
| PE20231379A1 (es) | 2023-09-07 |
| CO2023006514A2 (es) | 2023-07-31 |
| WO2022092908A1 (ko) | 2022-05-05 |
| CN116419757A (zh) | 2023-07-11 |
| IL302425A (en) | 2023-06-01 |
| JP2023548162A (ja) | 2023-11-15 |
| AU2021370071B2 (en) | 2024-01-11 |
| MX2023004654A (es) | 2023-05-18 |
| KR20220057469A (ko) | 2022-05-09 |
| EP4219471A4 (en) | 2024-03-13 |
| CA3195214A1 (en) | 2022-05-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2023006521A2 (es) | Forma cristalina iv del compuesto agonista de receptor de melanocortina y método de preparación para la misma | |
| CO2023006515A2 (es) | Forma cristalina i del compuesto agonista de receptor de melanocortina y método de preparación para la misma | |
| CL2023001222A1 (es) | Forma cristalina iii del compuesto agonista de receptor de melanocortina y método de preparación | |
| CO2023006517A2 (es) | Forma cristalina ii del compuesto agonista de receptor de melanocortina y método de preparación para la misma | |
| CL2023001221A1 (es) | Agonista del receptor de melanocortina-4 amorfo | |
| UY32096A (es) | Derivados de 2-carboxamida - cicloamino - urea especìficos, sus sales farmacèuticamente aceptables, composiciones contenièndolos, pro-farmacos de los mismos, procesos para su produciòn y aplicaciones | |
| EA201691119A1 (ru) | Производные мочевины или их фармакологически приемлемые соли | |
| UY31863A (es) | Combinaciones de drogas que comprenden un inhibidor de dgat y un agonista de ppar | |
| AR112276A1 (es) | Polimorfos de 5-fluoro-4-imino-3-metil-1-tosil-3,4-dihidropirimidin-2-ona | |
| UY36746A (es) | Método para la síntesis de derivados de rapamicina | |
| AR116790A1 (es) | PROCEDIMIENTO PARA LA PREPARACIÓN DE 3a-HIDROXI-5a-PREGNAN-20-ONA (BREXANOLONA) | |
| ES2531159T3 (es) | Compuestos y métodos para el tratamiento del cáncer | |
| MY185971A (en) | Pyranodipyridine compound | |
| MX2022009281A (es) | Inhibidores de rorgamma. | |
| CO2020006206A2 (es) | Polimorfos y formas sólidas de un compuesto de pirimidinilamino-pirazol y métodos de producción | |
| BR112018074287A2 (pt) | processo para preparação de eribulina e intermediários da mesma | |
| CU20190035A7 (es) | Derivados sustituidos de 6-(1h-pirazol-1-il)pirimidin-4-amina | |
| CY1115409T1 (el) | Νεο πολυμορφο του υδροχλωρικου αλατος του (4-υδροξυκαρβαμοϋλ-φαινυλ)καρβαμικου (6-διμεθυλαμινο μεθυλ-2-ναφθαλενυλ)εστερα | |
| BR112023022863A2 (pt) | Forma cristalina vii do composto agonista do receptor de melanocortina e método para preparar o mesmo | |
| BR112018009029A8 (pt) | corante, método para a produção de um corante, composição, artigo manufaturado e uso de um corante | |
| MX2019007573A (es) | Proceso de sisntesis de ditiocarbamatos ciclicos funcionalizados. | |
| BR112023022334A2 (pt) | Formas cristalinas de sulfato do composto agonista do receptor de melanocortina, seus métodos de preparação, seus usos, e composições farmacêuticas compreendendo as mesmas | |
| BR112023022532A2 (pt) | Forma cristalina do derivado de tiofeno e método de preparação do mesmo | |
| CU20220008A7 (es) | Forma polimórfica estable de 6-fluor0-9-metil-9h-b-carbolina | |
| MX367362B (es) | Nuevas formas solidas de desvenlafaxina. |